Cargando…

Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots

[Image: see text] The emergence of double mutation delta (B.1.617.2) variants has dropped vaccine effectiveness against SARS-CoV-2 infection. Although COVID-19 is responsible for more than 5.4 M deaths till now, more than 40% of infected individuals are asymptomatic carriers as the immune system of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pramanik, Avijit, Sharma, Poonam C., Patibandla, Shamily, Gao, Ye, Ruppa-Kasani, Vinod, Goli, Jagruti, Kumar, Animesh, Chatterjee, Abhirup, Sinha, Sudarson Sekhar, Bates, John T., Bierdeman, Michael A., Tandon, Ritesh, Ray, Paresh Chandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886715/
https://www.ncbi.nlm.nih.gov/pubmed/35252734
http://dx.doi.org/10.1021/acsomega.2c00113
_version_ 1784660737222770688
author Pramanik, Avijit
Sharma, Poonam C.
Patibandla, Shamily
Gao, Ye
Ruppa-Kasani, Vinod
Goli, Jagruti
Kumar, Animesh
Chatterjee, Abhirup
Sinha, Sudarson Sekhar
Bates, John T.
Bierdeman, Michael A.
Tandon, Ritesh
Ray, Paresh Chandra
author_facet Pramanik, Avijit
Sharma, Poonam C.
Patibandla, Shamily
Gao, Ye
Ruppa-Kasani, Vinod
Goli, Jagruti
Kumar, Animesh
Chatterjee, Abhirup
Sinha, Sudarson Sekhar
Bates, John T.
Bierdeman, Michael A.
Tandon, Ritesh
Ray, Paresh Chandra
author_sort Pramanik, Avijit
collection PubMed
description [Image: see text] The emergence of double mutation delta (B.1.617.2) variants has dropped vaccine effectiveness against SARS-CoV-2 infection. Although COVID-19 is responsible for more than 5.4 M deaths till now, more than 40% of infected individuals are asymptomatic carriers as the immune system of the human body can control the SARS-CoV-2 infection. Herein, we report for the first time that human host defense neutrophil α-defensin HNP1 and human cathelicidin LL-37 peptide-conjugated graphene quantum dots (GQDs) have the capability to prevent the delta variant virus entry into the host cells via blocking SARS-CoV-2 delta variant (B.1.617.2) spike protein receptor-binding domain (RBD) binding with host cells’ angiotensin converting enzyme 2 (ACE2). Experimental data shows that due to the binding between the delta variant spike protein RBD and bioconjugate GQDs, in the presence of the delta variant spike protein, the fluorescence signal from GQDs quenched abruptly. Experimental quenching data shows a nonlinear Stern–Volmer quenching profile, which indicates multiple binding sites. Using the modified Hill equation, we have determined n = 2.6 and the effective binding affinity 9 nM, which is comparable with the ACE2–spike protein binding affinity (8 nM). Using the alpha, beta, and gamma variant spike-RBD, experimental data shows that the binding affinity for the delta B.1.617.2 variant is higher than those for the other variants. Further investigation using the HEK293T-human ACE2 cell line indicates that peptide-conjugated GQDs have the capability for completely inhibiting the entry of delta variant SARS-CoV-2 pseudovirions into host cells via blocking the ACE2–spike protein binding. Experimental data shows that the inhibition efficiency for LL-37 peptide- and HNP1 peptide-attached GQDs are much higher than that of only one type of peptide-attached GQDs.
format Online
Article
Text
id pubmed-8886715
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-88867152022-03-01 Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots Pramanik, Avijit Sharma, Poonam C. Patibandla, Shamily Gao, Ye Ruppa-Kasani, Vinod Goli, Jagruti Kumar, Animesh Chatterjee, Abhirup Sinha, Sudarson Sekhar Bates, John T. Bierdeman, Michael A. Tandon, Ritesh Ray, Paresh Chandra ACS Omega [Image: see text] The emergence of double mutation delta (B.1.617.2) variants has dropped vaccine effectiveness against SARS-CoV-2 infection. Although COVID-19 is responsible for more than 5.4 M deaths till now, more than 40% of infected individuals are asymptomatic carriers as the immune system of the human body can control the SARS-CoV-2 infection. Herein, we report for the first time that human host defense neutrophil α-defensin HNP1 and human cathelicidin LL-37 peptide-conjugated graphene quantum dots (GQDs) have the capability to prevent the delta variant virus entry into the host cells via blocking SARS-CoV-2 delta variant (B.1.617.2) spike protein receptor-binding domain (RBD) binding with host cells’ angiotensin converting enzyme 2 (ACE2). Experimental data shows that due to the binding between the delta variant spike protein RBD and bioconjugate GQDs, in the presence of the delta variant spike protein, the fluorescence signal from GQDs quenched abruptly. Experimental quenching data shows a nonlinear Stern–Volmer quenching profile, which indicates multiple binding sites. Using the modified Hill equation, we have determined n = 2.6 and the effective binding affinity 9 nM, which is comparable with the ACE2–spike protein binding affinity (8 nM). Using the alpha, beta, and gamma variant spike-RBD, experimental data shows that the binding affinity for the delta B.1.617.2 variant is higher than those for the other variants. Further investigation using the HEK293T-human ACE2 cell line indicates that peptide-conjugated GQDs have the capability for completely inhibiting the entry of delta variant SARS-CoV-2 pseudovirions into host cells via blocking the ACE2–spike protein binding. Experimental data shows that the inhibition efficiency for LL-37 peptide- and HNP1 peptide-attached GQDs are much higher than that of only one type of peptide-attached GQDs. American Chemical Society 2022-02-22 /pmc/articles/PMC8886715/ /pubmed/35252734 http://dx.doi.org/10.1021/acsomega.2c00113 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Pramanik, Avijit
Sharma, Poonam C.
Patibandla, Shamily
Gao, Ye
Ruppa-Kasani, Vinod
Goli, Jagruti
Kumar, Animesh
Chatterjee, Abhirup
Sinha, Sudarson Sekhar
Bates, John T.
Bierdeman, Michael A.
Tandon, Ritesh
Ray, Paresh Chandra
Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots
title Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots
title_full Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots
title_fullStr Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots
title_full_unstemmed Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots
title_short Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots
title_sort blocking sars-cov-2 delta variant (b.1.617.2) spike protein receptor-binding domain binding with the ace2 receptor of the host cell and inhibiting virus infections using human host defense peptide-conjugated graphene quantum dots
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886715/
https://www.ncbi.nlm.nih.gov/pubmed/35252734
http://dx.doi.org/10.1021/acsomega.2c00113
work_keys_str_mv AT pramanikavijit blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT sharmapoonamc blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT patibandlashamily blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT gaoye blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT ruppakasanivinod blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT golijagruti blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT kumaranimesh blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT chatterjeeabhirup blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT sinhasudarsonsekhar blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT batesjohnt blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT bierdemanmichaela blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT tandonritesh blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots
AT raypareshchandra blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots